BioXcel Therapeutics (BTAI) Debt to Equity (2018 - 2026)

BioXcel Therapeutics' Debt to Equity history runs 9 years deep, the most recent figure standing at -$0.95 for Q1 2026.

• In Q1 2026, Debt to Equity rose 18.8% year-over-year to -$0.95; the TTM figure through Mar 2026 stood at -$0.95 (up 18.8% YoY), while the FY2025 annual figure was -$1.15, down 4.27% from the prior year.
• Debt to Equity was -$0.95 for Q1 2026 at BioXcel Therapeutics, up from -$1.15 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $16.66 in Q2 2023 to a low of -$2.46 in Q3 2023.
• Historically, Debt to Equity has averaged $0.35 across 5 years, with a median of -$1.1 in 2024.
• Biggest YoY gain for Debt to Equity was 623751.42% in 2023; the steepest drop was 439.44% in 2023.
• A 5-year view of Debt to Equity shows it stood at $1.22 in 2022, then plunged by 246.22% to -$1.78 in 2023, then jumped by 38.15% to -$1.1 in 2024, then slipped by 4.27% to -$1.15 in 2025, then rose by 17.23% to -$0.95 in 2026.
• The last three Debt to Equity figures came in at -$0.95 (Q1 2026), -$1.15 (Q4 2025), and -$1.23 (Q3 2025), per Business Quant data.